Relative Effectiveness of the MF59®-Adjuvanted Influenza Vaccine Versus High-Dose and Non-Adjuvanted Influenza Vaccines in Preventing Cardiorespiratory Hospitalizations During the 2019-2020 US Influenza Season.
Mahrukh ImranJoan Puig-BarberaJustin R OrtizLorena Lopez-GonzalezAlex DeanMachaon BonafedeMendel D M HaagPublished in: Influenza and other respiratory viruses (2024)
Relative to both HD-IIV3e and IIV4e, aIIV3 provided improved protection from cardiorespiratory or influenza hospitalizations.